L. Fedorova

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma

I. Moiseev, A. Kozlov, K. Lepik, 2021, International Journal of Clinical Oncology.

Efficacy and Safety of Pola-BR Combination in Relapsed/Refractory Aggressive В-Cell Non-Hodgkin’s Lymphomas: A Russian Multi-Center Study

L. Stelmakh, K. Lepik, N. Mikhailova, 2022, Clinical oncohematology.

A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

L. Stelmakh, I. Moiseev, B. Afanasyev, 2020, HemaSphere.

Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma

I. Moiseev, B. Afanasyev, A. Kozlov, 2021, Annals of Hematology.

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure

I. Moiseev, B. Afanasyev, K. Lepik, 2020, HemaSphere.

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations

I. Moiseev, K. Lepik, A. Kulagin, 2021, Cancers.

Autologous hematopoietic stem cell transplantation in children 13 with relapsed or refractory Hodgkin lymphoma

A. Shvetsov, N. Mikhailova, E. Morozova, 2022, Pediatric Hematology/Oncology and Immunopathology.

[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].

N. Mikhailova, V. A. Zherebtsova, O. Margolin, 2021, Terapevticheskii arkhiv.